Unlike genetic mutations, DNA methylation is a reversible process. This reversibility makes it a promising target for therapeutic interventions. Drugs known as DNA methyltransferase inhibitors (e.g., azacitidine and decitabine) are designed to demethylate DNA and reactivate silenced tumor suppressor genes. These drugs are currently used in the treatment of certain hematologic malignancies like myelodysplastic syndromes.
